Status:
COMPLETED
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Lead Sponsor:
Pfizer
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficac...
Eligibility Criteria
Inclusion
- Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints
- Active plaque psoriasis at screening
- Inadequate efficacy or lack of toleration to previously administered TNF inhibitor
Exclusion
- Non-plaque forms of psoriasis (with exception of nail psoriasis)
- History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
395 Patients enrolled
Trial Details
Trial ID
NCT01882439
Start Date
August 1 2013
End Date
April 1 2016
Last Update
September 15 2017
Active Locations (125)
Enter a location and click search to find clinical trials sorted by distance.
1
Rheumatology Associates P.C.
Birmingham, Alabama, United States, 35205
2
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States, 35801-4414
3
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, United States, 85306
4
Medvin Clinical Research
Covina, California, United States, 91723